Medtronic (NYSE: MDT) and Zynex (OTCMKTS:ZYXI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, earnings, risk, valuation and dividends.
This table compares Medtronic and Zynex’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Risk & Volatility
Medtronic has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, Zynex has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for Medtronic and Zynex, as reported by MarketBeat.com.
||Strong Buy Ratings
Medtronic presently has a consensus target price of $90.47, suggesting a potential upside of 12.78%. Given Medtronic’s stronger consensus rating and higher probable upside, analysts plainly believe Medtronic is more favorable than Zynex.
Medtronic pays an annual dividend of $1.84 per share and has a dividend yield of 2.3%. Zynex does not pay a dividend. Medtronic pays out 50.5% of its earnings in the form of a dividend. Medtronic has increased its dividend for 40 consecutive years.
Institutional and Insider Ownership
81.9% of Medtronic shares are held by institutional investors. 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Medtronic and Zynex’s revenue, earnings per share and valuation.
||Earnings Per Share
Medtronic has higher revenue and earnings than Zynex. Medtronic is trading at a lower price-to-earnings ratio than Zynex, indicating that it is currently the more affordable of the two stocks.
Medtronic beats Zynex on 12 of the 17 factors compared between the two stocks.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Zynex, Inc. operates through the Electrotherapy and Pain Management Products segment. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). Its other subsidiaries include Zynex Monitoring Solutions, Inc. (ZMS) and Zynex Europe, ApS (ZEU). ZMI designs, manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. ZMS is in the process of developing its blood volume monitoring product for non-invasive cardiac monitoring. ZEU intends to focus on sales and marketing its products within the international marketplace, upon receipt of necessary regulatory approvals. It markets and sells Zynex-manufactured products and distributes private labeled products. Its products include NexWave, NeuroMove, InWave, Electrodes and Batteries. ZMI devices are intended for pain management to reduce reliance on drugs and medications.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.